Structural studies on avidinorubicin, a novel anthracycline with platelet aggregation inhibitory activity.
Avidinorubicin (MW 1,214, C60H86N4O22) was isolated from the cultured broth of strain NR0576 (which was identified as Streptomyces avidinii Stapley et al.) by butyl alcohol extraction, Sephadex LH-20 column chromatography and preparative HPLC. Avidinorubicin inhibited thrombin-induced platelet aggregation with an IC50 being 7.9 microM and was determined to be a novel anthracycline possessing two units of a new aminosugar, avidinosamine, in place of two decilonitrose groups in decilorubicin.
Aoki
M
M
Nippon Roche Research Center, Kanagawa, Japan.
Shirai
H
H
Nakayama
N
N
Itezono
Y
Y
Mori
M
M
Satoh
T
T
Ohshima
S
S
Watanabe
J
J
Yokose
K
K
Seto
H
H
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000096:biosynthesis / Q000737:chemistry* / Q000302:isolation & purification / Q000494:pharmacology; D002850:Chromatography, Gel; D002851:Chromatography, High Pressure Liquid; D002855:Chromatography, Thin Layer; D005285:Fermentation; D006801:Humans; D006868:Hydrolysis; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D015394:Molecular Structure; D008970:Molecular Weight; D010975:Platelet Aggregation Inhibitors; D012988:Soil Microbiology; D013055:Spectrophotometry, Infrared; D013056:Spectrophotometry, Ultraviolet; D013302:Streptomyces / Q000145:classification / Q000378:metabolism*
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D010975:Platelet Aggregation Inhibitors; C069918:avidinorubicin